Kalaris Therapeutics, Inc. business relationships
Companies named in Kalaris Therapeutics, Inc.’s 10-K filed 2026-03-17, and public companies whose annual reports name Kalaris Therapeutics, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.2 / 10
- AI naming
- <1 / 100 Top 55% in its category
- Agent readiness
- 5 / 100
- AI adoption
- 0 / 100
Named in Kalaris Therapeutics, Inc.’s annual report 5
“...under the brand names Eylea® and EyleaHD®; brolucizumab, a single chain antibody fragment approved in 2019 and sold by Novartis AG under the brand name Beovu®; and faricimab, a bispecific antibody targeting both VEGF and angiopoietin-2, approved in 2022 and sold by Roche under the brand name Vabysm...” SEC filing
“...ng domains of VEGFR1 and VEGFR2, initially approved in 2011 and approved at a higher dose in 2023, is commercialized by Regeneron Pharmaceuticals, Inc. under the brand names Eylea® and EyleaHD®; brolucizumab, a single chain antibody fragment approved in 2019 and sold by Novartis AG under the brand n...” SEC filing
“Hoffmann-La Roche AG ("Roche") as Lucentis®; aflibercept, a fusion protein consisting of extracellular binding domains of VEGFR1 and VEGFR2, initially approved in 2011 and approved at a higher dose in 2023, is commercialized by Regeneron Pharmaceuticals, Inc. under the brand names Eylea® and EyleaHD...” SEC filing
“The Company recognized immaterial amounts for the years ended December 31, 2025 and 2024, as research and development expenses, related to the services provided by Samsara under the BSA.” SEC filing
“AbbVie is currently collaborating with RegenexBio Inc. ("RegenexBio") to develop ABBV-RGX-314 as a potential treatment for nAMD.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.